Neurodegenerative Focus Target ophthalmology and neurodegenerative indications with Galimedix’s Phase 2 portfolio including GAL-101 for geographic atrophy and next-gen oral Alzheimer’s candidates to align with high-value eye and brain disease markets.

Strategic Partnerships Leverage existing collaborations such as the Théa Open Innovation partnership to expand distribution, access Ophthalmology markets, and accelerate development through milestone-driven funding and co-development opportunities.

Clinical Milestones Capitalize on ongoing and upcoming presentations at major conferences (EURETINA, AD/PD) to generate interest from pharma and biotech buyers, potential licensees, and strategic partners seeking first-in-class neuroprotective therapies.

Clinical Validation Highlight Phase 1 safety and pharmacokinetics data for GAL-101 and preclinical data for GAL-201 to de-risk partnerships and attract co-development or out-licensing deals with larger players seeking early-stage assets.

Commercial Readiness Position as a nimble, specialty biopharma with eye and brain indications, offering scalable opportunities for in-licensing, co-development, or milestone-driven collaborations that fit standard biotech deal structures for mid-market assets.